Taking aim on bacterial pathogens: from phage therapy to enzybiotics

Current Opinion in Microbiology

Volumn 10, Issue 5, 2007, Pages 461-472

  Hermoso, Juan A ^a   García, José L ^b   García, Pedro ^b,c  

^a INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DISPERSIN B; ENDOLYSIN; ENZYME; HYDROLASE; LYSOSTAPHIN; PEPTIDOGLYCAN; PSEUDOMONIC ACID; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BIOTECHNOLOGICAL PROCEDURES; CATALYSIS; DISEASE MODEL; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME THERAPY; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; VIRION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; CELL WALL; ENDOPEPTIDASES; MODELS, MOLECULAR; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY; VIRAL PROTEINS; VIRION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 35948990424     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2007.08.002     Document Type: Review

References (62)

1. Skurnik M., and Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 296 (2006) 5-14
2. Hanlon G.W. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30 (2007) 118-128
3. Sandeep K. Bacteriophage precision drug against bacterial infections. Curr Sci 90 (2006) 361-363
4. Clark J.R., and March J.B. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 24 (2006) 212-218
5. Fischetti V.A., Nelson D., and Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat Biotechnol 12 (2006) 1508-1511
6. Kutter E., and Sulakvelidze A. Introduction. In: Kutter E., and Sulakvelidze A. (Eds). Bacteriophages Biology and Applications (2005), CRC Press, Boca Raton 1-4
7. Thiel K. Old dogma, new tricks-21st century phage therapy. Nat Biotechnol 22 (2004) 31-36
8. Górski A., and Weber-Da{ogonek}browska B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62 (2005) 511-519
9. Górski A., Ważna E., Weber-Da{ogonek}browska B., Da{ogonek}browska K., Świtała-Jeleń K., and Mie{ogonek}dzybrodzki R. Bacteriophage translocation. FEMS Immunol Med Microbiol 46 (2006) 313-319
10. López R., García E., and García P. Enzymes for anti-infective therapy: phage lysins. Drug Discov Today Ther Strat 1 (2004) 469-474
11. Brüssow H. Phages of dairy bacteria. Annu Rev Microbiol 55 (2001) 283-303
12. Scholl D., Rogers S., Adhya S., and Merril C. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol 75 (2001) 2509-2515
13. Lu T.K., and Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 104 (2007) 11197-11202. A study that reveals that an engineered phage expressing biofilm-degrading enzymes is more efficient at removing bacterial biofilms than non-enzymatic phage alone. This treatment may become an additional tool to the standard therapies for use against bacterial biofilms in different settings.
14. Mushtaq N., Redpath M.B., Luzio J.P., and Taylor P.W. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother 48 (2004) 1503-1508
15. Jikia D., Chkhaidze N., Imedashvili E., Mgaloblishvili I., Tsilanadze G., Katsarava R., Morris Jr. J.G., and Sulakvelidze A. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol 30 (2005) 23-26
16. Borysowski J., Weber-Da{ogonek}browska B., and Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 231 (2006) 366-377
17. Loessner M.J. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 8 (2005) 480-487
18. Moak M., and Molineux I.J. Peptidoglycan hydrolytic activities associated with bacteriophage virions. Mol Microbiol 51 (2004) 1169-1183
19. Kanamaru S., Ishiwata Y., Suzuki T., Rossmann M.G., and Arisaka F. Control of bacteriophage T4 tail lysozyme activity during the infection process. J Mol Biol (2005) 1013-1020
20. Nelson D., Schuch R., Chahales P., Zhu S., and Fischetti V.A. PlyC: a multimeric bacteriophage lysine. Proc Natl Acad Sci USA 103 (2006) 10765-10770. This study describes the first example of a multimeric endolysin composed of two separate gene products.
21. Scheurwater E, Reid CW, Clarke AJ: Lytic transglycosylases: Bacterial space-making autolysins. Int J Biochem Cell Biol 2007, doi:10.1016/j.biocel.2007.03.018, in press.
22. Xu M., Arulandu A., Struck D.K., Swanson S., Sacchettini J.C., and Young R. Disulfide isomerization after membrane release of its SAR domain activates P1 lysozyme. Science 307 (2005) 113-117. A very interesting study showing the structural changes involved in export and activation of the secreted but transiently membrane-tethered P1 signal arrest release (SAR) endolysin.
23. Stojković E.A., and Rothman-Denes L.B. Coliphage N4 N-acetylmuramidase defines a new family of murein hydrolases. J Mol Biol 366 (2007) 406-419. This study describes a new coliphage-encoded murein hydrolase that localizes primarily to the cell inner membrane and that represents the first primary structure of a new family of muramidases.
24. Rigden D.J., Jedrzejas M.J., and Galperin M.Y. Amidase domains from bacterial and phage autolysins define a family of γ-d,l-glutamate-specific amidohydrolases. Trends Biochem Sci 28 (2003) 230-234
25. López R., and García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol Rev 28 (2004) 553-580
26. Hermoso J.A., Lagartera L., González A., Stelter M., García P., Martínez-Ripoll M., García J.L., and Menéndez M. Insights into pneumococcal pathogenesis from the crystal structure of the modular teichoic acid phosphorylcholine esterase Pce. Nat Struct Mol Biol 12 (2005) 533-538
27. Boneca I.G., Dussurget O., Cabanes D., Nahori M.A., Sousa S., Lecuit M., Psylinakis E., Bouriotis V., Hugot J.P., Giovannini M., et al. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci USA 104 (2007) 997-1002
28. Hermoso J.A., Monterroso B., Albert A., Galán B., Ahrazem O., García P., Martínez-Ripoll M., García J.L., and Menéndez M. Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11 (2003) 1239-1249
29. Buey R.M., Monterroso B., Menéndez M., Diakun G., Chacón P., Hermoso J.A., and Díaz J.F. Insights into molecular plasticity of choline binding proteins (pneumococcal surface proteins) by SAXS. J Mol Biol 365 (2007) 411-424
30. Porter C.J., Schuch R., Pelzek A.J., Buckle A.M., McGowan S., Wilce M.C.J., Rossjohn J., Russell R., Nelson D., Fischetti V.A., and Whisstock J.C. The 1.6 Å crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J Mol Biol 366 (2007) 540-550
31. Rau A., Hogg T., Marquardt R., and Hilgenfeld R. A new lysozyme fold. Crystal structure of the muramidase from Streptomyces coelicolor at 1.65 Å resolution. J Biol Chem 276 (2001) 31994-31999
32. Lu J.Z., Fujiwara T., Komatsuzawa H., Sugai M., and Sakon J. Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. J Biol Chem 281 (2006) 549-558
33. Mooers B.H.M., and Matthews B.W. Extension to 2268 atoms of direct methods in the ab initio determination of the unknown structure of bacteriophage P22 lysozyme. Acta Cryst Sect D 62 (2006) 165-176
34. Low L.Y., Yang C., Perego M., Osterman A., and Liddington R.C. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem 280 (2005) 35433-35439. This study presents the crystal structure of the catalytic module of PlyL endolysin. Lytic activity of the catalytic module is higher than full-length protein. Authors propose an interesting model in which cell wall binding module only allows the catalytic module to function in the presence of a specific cell wall.
35. Cheng X., Zhang X., Pflugrath J.W., and Studier F.W. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. Proc Natl Acad Sci USA 91 (1994) 4034-4038
36. Liepinsh E., Genereux C., Dehareng D., Joris B., and Otting G. NMR structure of Citrobacter freundii AmpD, comparison with bacteriophage T7 lysozyme and homology with PGRP domains. J Mol Biol 327 (2003) 833-842
37. Kim M.S., Byun M., and Oh B.H. Crystal structure of peptidoglycan recognition protein LB from Drosophila melanogaster. Nat Immunol 4 (2003) 787-793
38. Korndörfer I.P., Danzer J., Schmelcher M., Zimmer M., Skerra A., and Loessner M.J. The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for specific recognition of Listeria cell walls. J Mol Biol 364 (2006) 678-689. This study presents the complete structure of an endolysin (PlyPSA), carrying both the catalytic and cell wall binding (CWBM) modules. The CWBM features a novel fold that has an internal duplication of a β-barrel-like motif.
39. *. J Biol Chem 276 (2001) 28140-28146
40. Pérez-Dorado I., Campillo N.E., Monterroso B., Hesek D., Lee M., Páez J.A., García P., Martínez-Ripoll M., García J.L., Mobashery S., et al. Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1. J Biol Chem 282 (2007) 24990-24999. This report provides for the first time a structural picture at the atomic level of the interaction between a pneumococcal endolysin (Cpl-1) and its substrate, the bacterial peptidoglycan. This work demonstrates how this enzyme recognizes the peptidoglycan and reveals in detail the complexity underlying the binding and the mechanism of the hydrolytic activity of Cpl-1. This analysis is the first for a member of the glycosyl hydrolase family 25.
41. Meroueh S.O., Bencze K.Z., Hesek D., Lee M., Fisher J.F., Stemmler T.L., and Mobashery S. Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc Natl Acad Sci USA 103 (2006) 4404-4409
42. Krause R.M. Studies on bacteriophages of hemolytic streptococci. I. Factors influencing the interaction of phage and susceptible host cell. J Exp Med 106 (1957) 365-384
43. Nelson D., Loomis L., and Fischetti V.A. Prevention and elimination colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98 (2001) 4107-4112
44. Yoong P., Schuch R., Nelson D., and Fischetti V.A. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 186 (2004) 4808-4812
45. Zimmer M., Vukov N., Scherer S., and Loessner M.J. The murein hydrolase of the bacteriophage φ{symbol}3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl Environ Microbiol 68 (2002) 5311-5317
46. Cheng Q., Nelson D., Zhu S., and Fischetti V.A. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49 (2005) 111-117
47. Schuch R., Nelson D., and Fischetti V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418 (2002) 884-889
48. Jado I., López R., García E., Fenoll A., Casal J., and García P. Phage lytic enzymes as therapy for antibiotic resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 52 (2003) 967-973
49. McCullers J.A., Karlström Ǻ., Iverson A.R., Loeffler J.M., and Fischetti V.A. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3 (2007) e28. An elegant study from Fischetti's lab where the first mouse model of acute otitis media in which infection develops similarly to that observed in children was set up. Once again, purified Cpl-1, the lysozyme encoded by the pneumococcal phage Cp-1, demonstrated its potent killing effect against pneumococci.
50. Kokai-Kun J.F., Walsh S.M., Chanturiya T., and Mond J.J. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47 (2003) 1589-1597
51. Turner M.S., Waldherr F., Loessner M.J., and Giffard P.M. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Syst Appl Microbiol 30 (2007) 58-67
52. Wall R.J., Powell A.M., Paape M.J., Kerr D.E., Bannerman D.D., Pursel V.G., Wells K.D., Talbot N., and Hawk H.W. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat Biotechnol 23 (2005) 445-451
53. Rodríguez-Cerrato V., García P., Huelves L., García E., del Prado G., Gracia M., Ponte C., López R., and Soriano F. Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly β-lactam-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 51 (2007) 3371-3373. The first demonstration of the powerful action of the purified major pneumococcal autolysin, amidase LytA, to act as a true enzybiotic in a mouse model.
54. Loeffler J.M., Djurkovic S., and Fischetti V.A. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71 (2003) 6199-6204
55. Bernhardt T.G., Wang I.-N., Struck D.K., and Young R. Breaking free: "protein antibiotics" and phage lysis. Res Microbiol 153 (2002) 493-501
56. Westwater C., Kasman L.M., Schofield D.A., Werner P.A., Dolan J.W., Schmidt M.G., and Norris J.S. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47 (2003) 1301-1307
57. Hagens S., Habel A., and Bläsi U. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microb Drug Resist 12 (2006) 164-168
58. Donovan D.M., Dong S., Garrett W., Rousseau G.M., Moineau S., and Pritchard D.G. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl Environ Microbiol 72 (2006) 2988-2996
59. Loeffler J.M., Nelson D., and Fischetti V.A. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294 (2001) 2170-2172
60. Djurkovic S., Loeffler J.M., and Fischetti V.A. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 49 (2005) 1225-1228
61. Rodríguez-Cerrato V., García P., del Prado G., García E., Gracia M., Huelves L., Ponte C., López R., and Soriano F. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains. J Antimicr Chemother 60 (2007) 1159-1162
62. Entenza J.M., Loeffler J.M., Grandgirard D., Fischetti V.A., and Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49 (2005) 4789-4792